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Randomized Phase III Trial of Docetaxel Plus Carboplatin
with or without Levofloxacin Prophylaxis in Elderly Patients
with Advanced Non-small Cell Lung Cancer
The APRONTA Trial
Wolfgang Schuette, PhD, MD,* Sylke Nagel, MD,* Ludwig Fischer von Weikersthal, MD,†
Stefan Pabst, MD,‡ Christian Schumann, PhD, MD,§ Burkhard Deuss, MD, Thorsten Salm, MD,¶
Katrin Roscher, MD,¶ and Nicolas Dickgreber, MD#
Purpose: To examine the effect of levofloxacin prophylaxis on
infection rates during chemotherapy with docetaxel plus carboplatin
in elderly patients with advanced non-small cell lung cancer.
Methods: In a randomized, double-blind, phase III study, patients
(65 years) with untreated, histologically/cytologically proven
stage IIIB/IV non-small cell lung cancer received docetaxel (75
mg/m2) plus carboplatin (area under the curve 6) on day 1 every 3
weeks, plus once-daily levofloxacin (500 mg orally) or placebo on
days 5 to 11. The primary end point was the rate of grade 3/4
infections or grade 1/2 infections treated with additional antibiotics.
Secondary end points included overall infection rate, toxicity, over-
all survival, and progression-free survival.
Results: In total, 187 patients were randomized to levofloxacin (n
95) or placebo (n 92). The rate of grade 3/4 infections or grade 1/2
infections treated with additional antibiotics (intent-to-treat popula-
tion) was 27.5% (95% confidence interval, 19.3–39.0%) for levo-
floxacin versus 36.7% (95% confidence interval, 27.1–48.0%) for
placebo. Median time to first infection was 67 days for levofloxacin
versus 46 days for placebo. Grade 3/4 infections occurred in 8.8% of
patients in the levofloxacin group versus 26.7% for placebo. There
was one grade 5 infection in each group. Grade 3 toxicities
(levofloxacin versus placebo) included leukopenia (63.2 versus
52.2%), neutropenia (62.1 versus 51.1%), dyspnea (12.6 versus
8.7%), and pain (10.5 versus 9.8%). There was no significant
difference in overall survival or progression-free survival between
groups.
Conclusions: Levofloxacin prophylaxis reduces the rate of infection
compared with placebo and is well tolerated in elderly patients
receiving docetaxel plus carboplatin.
Key Words: Chemotherapy, Elderly, Levofloxacin, NSCLC,
Prophylaxis.
(J Thorac Oncol. 2011;6: 2090–2096)
Lung cancer is the leading cause of cancer mortality in theUnited States.1 The probability of developing invasive
lung cancer rises from 0.03% in people aged 39 years to
6.74% in men and 4.61% in women aged 70 years.1
Advanced (stage IIIB/IV) non-small cell lung cancer
(NSCLC) accounts for the majority of newly diagnosed
cases.2 Stage IV disease is associated with 5-year survival
rates of 5%.2
Platinum-based combination chemotherapy regimens
are currently used in the first-line setting for the treatment of
advanced NSCLC,3 but there are concerns about their toler-
ability in older patients.4 In particular, there is increasing
concern about hematologic toxicity in older patients
treated with chemotherapy, because they are more likely
than younger patients to experience febrile neutropenia
and infection.5
In the phase III TAX 326 study of first-line chemother-
apy in patients with stage IIIB/IV NSCLC, treatment with
docetaxel in combination with carboplatin led to similar
survival and response rates, but a more favorable safety
profile and quality of life score compared with vinorelbine
plus cisplatin.6,7 Subgroup analysis of TAX 326 showed
similar survival outcomes in elderly patients (aged 65
years) compared with younger patients.8,9 Nevertheless, in
this analysis, the rate of febrile neutropenia in patients aged
65 years who received docetaxel plus carboplatin was
higher than in patients 65 years of age who received this
regimen (7.0 versus 2.4%, respectively).8 Elderly patients
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were also more likely to experience grade 3/4 infection
during docetaxel plus carboplatin therapy.
One potential strategy to minimize the risk of infection
during chemotherapy is the prophylactic use of an antibacte-
rial agent. Levofloxacin is a once-daily, broad-spectrum oral
fluoroquinolone antibiotic with proven clinical efficacy and
acceptable tolerability in the treatment of bacteriologically
documented infections of the respiratory and urinary tracts.10
The prophylactic use of fluoroquinolone antibiotics in pa-
tients with cancer has been questioned because of the lack of
supporting evidence from placebo-controlled trials and the
potential for the development of bacterial resistance to fluo-
roquinolones.11 However, previous phase III studies suggest
that prophylaxis with levofloxacin is effective at reducing the
incidence of bacterial infections in patients with cancer.12,13
Here, we report the results of the APRONTA trial,
which examined the effect of levofloxacin prophylaxis on
infection rates during chemotherapy with docetaxel plus car-
boplatin in older patients (65 years) with advanced
NSCLC.
PATIENTS AND METHODS
This randomized, double-blind, placebo-controlled
phase III trial compared the efficacy and tolerability of
docetaxel plus carboplatin with versus without prophylactic
levofloxacin in patients aged 65 years with previously
untreated histologically or cytologically proven stage IIIB/IV
NSCLC.
The primary end point was the rate of grade 3/4
infections or grade 1/2 infections treated with additional
antibiotics in the intent-to-treat (ITT) population within the
period from the first administration of antibiotic or placebo
until the first follow-up visit 4 weeks after the final therapy
cycle. Secondary end points included toxicity, response rate,
1-year survival, overall survival (OS), progression-free sur-
vival (PFS), and overall infection rate.
Patient Selection
Patients were required to meet the following inclusion
criteria: age 65 years; inoperable histologically or cytolog-
ically proven stage IIIB/IV NSCLC; no prior chemotherapy
for advanced disease; 1 lesion measurable by computed
tomography or radiography; Eastern Cooperative Oncology
Group performance status 2; life expectancy 12 weeks;
and normal cardiac, renal, hepatic, and hematologic function
(neutrophils 2  109/L; aspartate aminotransferase and
alanine aminotransferase 1.5  upper limit of normal
[ULN]; alkaline phosphatase2.5 ULN; platelets100
109/L; total bilirubin ULN; creatinine 1.5  ULN). All
patients had to provide written informed consent before
study entry.
Patients were excluded from the study if they had active
infection or had received antibiotics within 72 hours before
enrollment; a history of a second malignancy (except basal
cell carcinoma of the skin or curatively treated carcinoma in
situ of the cervix); maintenance treatment with corticoste-
roids or other immunosuppressive agents; concurrent radia-
tion therapy or other tumor-specific therapy; preexisting neu-
ropathy (sensory or motor) grade 2 according to National
Cancer Institute Common Toxicity Criteria (NCI-CTC) Ver-
sion 3.0; central nervous system metastases; epilepsy; tendon
disease; heart failure; or any other serious medical condition.
Treatment Plan
Patients were randomized 1:1 to receive docetaxel (75
mg/m2 intravenously [IV], day 1) plus carboplatin (area under
the curve 6, IV, day 1) every 3 weeks plus either placebo or
levofloxacin (500 mg orally) once daily on days 5 to 11 of
each 3-week cycle. Patients were to receive four to six cycles
of treatment unless tumor progression or unacceptable toxic-
ity occurred, or the patient withdrew their consent. Treatment
could continue beyond six cycles at the physician’s discretion
without further administration of levofloxacin or placebo.
Toxicity was assessed during the treatment period ac-
cording to NCT-CTC Version 3.0. Therapy could be delayed
because of toxicity for a maximum of 3 weeks. If a delay of
longer than 3 weeks was required, the patient was withdrawn
from the study. The chemotherapy dose could also be reduced
if considered necessary because of toxicity (docetaxel re-
duced to 60 mg/m2 and carboplatin reduced to area under the
curve 4.5 in one step). Reescalation to the original dose was
at the physician’s discretion. Patients were allowed one
further dose reduction after reescalation; beyond that their
participation in the study was discontinued. If a grade 3/4
infection, or a lower grade infection requiring systemic anti-
biotic therapy, was observed, chemotherapy was continued
according to protocol but the antibiotic prophylaxis/placebo
administration was stopped. Infections requiring systemic
antibiotic therapy were treated at the discretion of the physi-
cian. Patients who developed grade 4 neutropenia that lasted
for more than 7 days or that was accompanied by fever were
treated with a nonfluoroquinolone antibiotic and received
prophylactic granulocyte colony-stimulating factor during the
subsequent treatment cycles. All patients received premedi-
cation with oral dexamethasone (8 mg twice daily), or an
equivalent dose of corticosteroids, for 2.5 days starting 24
hours before docetaxel administration. An equivalent IV dose
of dexamethasone was administered 30 minutes before do-
cetaxel infusion. Antiemetics were given as necessary.
Baseline and Treatment Evaluations
Demographics, disease characteristics, laboratory tests,
and image-guided procedures were recorded at baseline.
Infections were classified based on NCI-CTC Version 3.0 and
were defined as any occurrence with signs of localized
infection, with or without fever (38°C), and with or without
microbiologic documentation, and septicemia verified by mi-
crobiologic testing (modified according to the criteria of the
German Society of Hematology and Oncology).14 The infec-
tion rate was assessed during the observation period between
the first administration of antibiotic/placebo until the first
follow-up visit 4 weeks after administration of the final
treatment cycle.
Tumor evaluation was performed according to Re-
sponse Evaluation Criteria in Solid Tumors15 following every
second cycle of chemotherapy. OS was defined as the time
between randomization and death, and PFS was defined as
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the time between the first administration of study medication
and the first evidence of progression or death.
Safety was evaluated by the number of adverse events
(including outcome status) and the number of NCI-CTC
toxicities after every chemotherapy cycle and every 3 months
during follow-up. Serious adverse events were defined as
those resulting in death, and those that were life threatening,
required hospital treatment or prolonged hospitalization, re-
sulted in disability, or were considered to be of medical
significance. Laboratory parameters, including hematology,
serum chemistry, and creatinine clearance, were assessed
before each new treatment cycle, and blood counts were
monitored weekly.
Statistical Methods
A sample size of 200 patients was considered to be
sufficient based on estimated rates of infection of 20% in the
placebo group and 5% in the levofloxacin group (two-sided
test with   0.05 and   0.20) and the expected follow-up
loss of approximately 10%.
Descriptive statistical methods were used and included
frequency counts and summary statistics with mean, SD,
median, range, and first and third quartiles. Comparisons
between the treatment groups were performed using Fisher
exact test; 95% confidence intervals (CIs, exact method) were
provided for the rates of infection. Kaplan–Meier survival
analyses and log-rank tests were conducted for time-to-event
variables.
The primary analysis population was the ITT popula-
tion, which included all randomized patients who received at
least one administration of prophylaxis with levofloxacin or
placebo. Tumor response was evaluated in all patients who
received at least one complete course of docetaxel. The safety
population comprised all patients who received at least one
cycle of docetaxel therapy. Additional analyses were con-
ducted on November 28, 2008, for the ITT population and 11
subgroups. Results from the subgroup analysis according to
age (70 years or 70 years) are presented here.
RESULTS
Patients
Overall, 192 patients were enrolled at 26 centers in
Germany between May 7, 2004, and February 18, 2008.
Patients were randomized to docetaxel plus carboplatin and
either levofloxacin (n  99) or placebo (n  93) (Figure 1);
five patients received no treatment and were therefore ex-
cluded from the ITT population. Overall, 30 of 95 patients
(32%) in the levofloxacin group and 31 of 92 patients (34%)
in the placebo group completed the study. Disease progres-
sion was the most frequent cause of study discontinuation in
both groups. The median number of treatment cycles was 4 in
each treatment group.
Demographic and baseline disease characteristics were
mostly well balanced between the two treatment groups
(Table 1), with the exception of Eastern Cooperative Oncol-
ogy Group performance status (slightly worse in the placebo
group) and disease stage (a higher proportion of patients with
stage IV disease in the placebo group). More than 40% of
patients in each group had lymph node involvement and more
than 10% had liver metastases.
Randomized n = 192
Placebo n = 93
Docetaxel 75 mg/m2 plus carboplatin
AUC 6, day 1 every 3 weeks,
plus prophylaxis with placebo
on days 5–11
Levofloxacin n = 99
Docetaxel 75 mg/m2 plus carboplatin
 AUC 6, day 1 every 3 weeks,
plus prophylaxis with levofloxacin
500 mg once daily, on days 5–11
Discontinuations n = 65
Progression n = 20
Toxicity n = 16
Patient’s wish n = 10
Other reason n = 8
Death n = 7
Lost to follow-up n = 2
Toxicity and patient’s wish n = 2
Discontinuations n = 61
Progression n = 27
Toxicity n = 9
Patient’s wish n = 9
Other reason n = 8
Death n = 8
Lost to follow-up n = 0
Toxicity and patient’s wish n = 0
Completed planned therapy n = 31
Excluded due to lack of treatment n = 1
Excluded due to lack of prophylaxis n = 2 Excluded due to lack of prophylaxis n = 4
Excluded due to lack of treatment n = 4
Completed planned therapy n = 30
ITT population n = 92 ITT population n = 95
ITT population for primary efficacy
analysis and time to infection n = 90
ITT population for primary efficacy
analysis and time to infection n = 91FIGURE 1. Patient flow. AUC, area
under the curve; ITT, intent-to-treat.
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Infection
For the primary efficacy end point, six patients without
prophylaxis with placebo/levofloxacin were excluded from
the ITT population. The rate of grade 3/4 infections or grade
1/2 infections treated with additional antibiotics (the primary
end point) was 27.5% (95% CI, 19.3–39.0%) for levofloxacin
and 36.7% (95% CI, 27.1–48.0%) for placebo (Table 2).
The infection rate was higher in the placebo group
compared with the levofloxacin group, but this difference did
not reach statistical significance (Fisher exact test, p 0.263;
Table 3). The median (range) time to first infection was 46
(2–411) days for placebo and 67 (0–279) days for levofloxa-
cin. A time to first infection of 0 days indicates an infection
with onset on the first day of antibiotic prophylaxis.
Additional analysis revealed that the greatest between-
group difference in median time to first infection was in the
subgroup of patients aged 70 years (69 and 27 days for
levofloxacin and placebo, respectively; Table 3).
A larger proportion of patients in the placebo group
experienced grade 3/4 infections than in the levofloxacin
group (26.7 versus 8.8%, respectively; Table 2). There was
one case of grade 5 infection in each group. One patient in the
placebo group experienced fever, grade 3/4 neutropenia, and
grade 5 sepsis, and one patient in the levofloxacin group
presented with fever, grade 3/4 urinary tract infection, grade
4 candidiasis, and grade 5 urosepsis. The most common
infection was pneumonia (21.7 and 11.6% in the placebo and
levofloxacin groups, respectively) (Table 4).
Fever was experienced by 23.9% of patients in the
placebo group and 16.8% of those in the levofloxacin group.
Grade 3/4 neutropenia was reported as a symptom in 18.5%
of patients in the placebo group versus 16.8% in those treated
with levofloxacin.
Efficacy
The median follow-up was 8 months for both treatment
groups combined. Overall tumor response rates (complete or
partial response) were 30.4 and 29.5% in the placebo and
levofloxacin groups, respectively (p  1.0 based on Fisher
exact test).
At the data cut-off for the final analysis (November 28,
2008), there had been 64 deaths in the placebo group and 64
in the levofloxacin group. No significant improvements in OS
were observed with levofloxacin prophylaxis compared with
placebo. The median OS was 314 days in the placebo group
and 307 days in the levofloxacin group and hence was
TABLE 1. Baseline Characteristics (Intent-to-Treat
Population)
Baseline Characteristic
Placebo
(n  92)
Levofloxacin
(n  95)
Mean age, yr (range) 70.7 (59–83) 70.8 (62–79)
Sex, n (%)
Male 74 (80.4) 76 (80.0)
Female 18 (19.6) 19 (20.0)
ECOG performance status, n (%)
0 28 (30.4) 40 (42.1)
1 56 (60.9) 47 (49.5)
2 8 (8.7) 8 (8.4)
Diagnosis, n (%)
Adenocarcinoma 45 (48.9) 50 (52.6)
Squamous cell carcinoma 36 (39.1) 28 (29.5)
Other NSCLC 8 (8.7) 10 (10.5)
Large cell carcinoma 3 (3.3) 7 (7.4)
Disease stage, n (%)
IIIB 16 (17.4) 31 (32.6)
IV 76 (82.6) 63 (66.3)
Unknown 0 1 (1.1)
Prior therapy, n (%)
None 76 (82.6) 77 (81.1)
Surgery 10 (10.9) 9 (9.5)
Radiotherapy 3 (3.3) 6 (6.3)
Radiotherapy for metastases 3 (3.3) 5 (5.3)
Laser therapy 1 (1.1) 2 (2.1)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
TABLE 2. Rates of Infection (Intent-to-Treat Population)
Grade of Infection
No. of Patients
With Infection (%)
Placebo
(n  90)a
Levofloxacin
(n  91)a
1  additional antibiotic therapy 0 (0) 5 (5.5)
2  additional antibiotic therapy 8 (8.9) 11 (12.1)
3 19 (21.1) 7 (7.7)
4 5 (5.6) 1 (1.1)
5b 1 (1.1) 1 (1.1)
All 33 (36.7) 25 (27.5)
95% CI 27.1–48.0 19.3–39.0
a Six patients (two placebo, four levofloxacin) were not included in the analysis
because they did not receive prophylaxis with placebo/antibiotic.
b Only the highest grade was documented for each event.
CI, confidence interval.
TABLE 3. Infection Rates and Time to First Infection
(Intent-to-Treat Population)
Treatment Group
Patients With
Infection, %
(95% CI)
Median (Range)
Time to First
Infection,a d
ITT analysisb
Placebo (n  90) 36.7 (27.1–48.0) 46 (2–411)
Levofloxacin (n  91) 27.5 (19.3–39.0) 67 (0–279)
Additional analysis
Placebo (n  90)b
70 yr (n  49) 36.7 (24.0–52.7) 69 (2–125)
70 yr (n  41) 36.6 (22.1–53.1) 27 (2–411)
Levofloxacin (n  91)b
70 yr (n  44) 29.6 (17.2–46.1) 65 (0–279)
70 yr (n  47) 25.5 (14.6–41.9) 69 (1–154)
a Time between first prophylactic treatment with antibiotics/placebo and the start of
infection.
b Six patients (two placebo, four levofloxacin) were not included in the analysis
because they did not receive prophylaxis with placebo/antibiotic.
CI, confidence interval.
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comparable for both treatment groups (hazard ratio, 0.83;
95% CI, 0.58–1.17; p  0.28; Figure 2).
PFS results for the two groups were similar (84.8% for
placebo versus 83.2% for levofloxacin). Median PFS was
greater in the levofloxacin group (121 days for placebo versus
165 days for levofloxacin), but this difference did not reach
statistical significance (hazard ratio, 0.82; 95% CI, 0.60–
1.13; p 0.22; Figure 3). If deaths occurring later than 1 year
after randomization are censored, the 1-year OS rate was
33.7% in the placebo group and 36.8% in the levofloxacin
group.
Toxicity
Grade 3 toxicities included leukopenia (52.2 placebo
versus 63.2% levofloxacin), neutropenia (51.1 versus 62.1%),
dyspnea (8.7 versus 12.6%), thrombocytopenia (12.0 versus
7.4%), diarrhea (10.9 versus 3.2%), pain (9.8 versus 10.5%),
anemia (7.6 versus 2.1%), mucositis (0 versus 5.3%), asthe-
nia (4.3 versus 1.0%), febrile neutropenia (3.3 versus 4.2%),
TABLE 4. Infection Events (Intent-to-Treat Population)a
Grade of Infection
No. of Patients With
Infection, n (%)
Placebo (n  92) Levofloxacin (n  95)
All Grades Grade >3 All Grades Grade >3
Pneumonia 20 (21.7) 12 (13.0) 11 (11.6) 6 (6.3)
Sepsis 4 (4.3) 4 (4.3) 1 (1.1) 1 (1.1)
Febrile neutropenia 3 (3.3) 3 (3.3) 4 (4.2) 4 (4.2)
Urinary tract infection 2 (2.2) 0 3 (3.2) 1 (1.1)
Acute exacerbation of
chronic bronchitis
1 (1.1) 0 1 (1.1) 0
Other 15 (16.3) 4 (4.3) 22 (23.2) 5 (5.3)
Unknown 2 (2.2) —a 1 (1.1) —b
a Includes six patients (two placebo, four levofloxacin) who did not receive
prophylaxis.
b No. of patients unknown because the grade of infection was not documented.
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FIGURE 2. Kaplan-Meier analysis of overall
survival (intent-to-treat population). Median
overall survival: placebo, 314 days; levofloxa-
cin, 307 days; hazard ratio, 0.83 (95% confi-
dence interval, 0.58–1.17); log rank, p  0.28.
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FIGURE 3. Kaplan-Meier analysis of progres-
sion-free survival (intent-to-treat population).
Median progression-free survival: placebo, 121
days; levofloxacin, 165 days; hazard ratio, 0.82
(95% confidence interval, 0.60–1.13); log
rank, p  0.22.
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nausea (1.1 versus 3.2%), vomiting (0 versus 3.2%), and
candidiasis (0 versus 1.1%). In the subgroup of patients aged
70 years, the most common grade 3 toxicities were
neutropenia (70% placebo versus 59.6% levofloxacin), leu-
kopenia (56.1 versus 59.6%), diarrhea (19.5 versus 2.1%),
dyspnea (7.3 versus 17%), and pain (14.6 versus 8.5%).
DISCUSSION
Infections as sequelae of hematologic toxicity remain a
leading cause of death in patients receiving chemotherapy for
advanced NSCLC, despite improvements in survival rates
through the use of platinum-based combination regimens.16
This phase III randomized placebo-controlled trial demon-
strated that the prophylactic use of levofloxacin with first-line
docetaxel/carboplatin chemotherapy is well tolerated and is
associated with a reduction in the rate of infection compared
with placebo prophylaxis in elderly patients with advanced
NSCLC. Furthermore, the median time to first infection was
prolonged in the levofloxacin group (67 versus 46 days for
levofloxacin versus placebo). No survival advantage was
demonstrated in patients who received levofloxacin prophy-
laxis, but median OS was comparable with that reported in
other studies of docetaxel/carboplatin chemotherapy in el-
derly patients with advanced NSCLC.8,9
Fluoroquinolones are widely used for prophylaxis dur-
ing chemotherapy.17 However, this practice is not recom-
mended in the most recent guidelines published by the Infec-
tious Diseases Society of America.11 This is largely because
of the lack of data from randomized trials and the failure to
demonstrate a survival advantage with this approach. Several
phase III studies have now shown that prophylaxis with
levofloxacin is effective at reducing the incidence of bacterial
infections and febrile neutropenia in patients with solid tu-
mors or lymphoma.12,13 In addition, a meta-analysis of pa-
tients with neutropenia found that fluoroquinolone prophy-
laxis was associated with a significant reduction in the
incidence of febrile episodes and a trend toward decreased
mortality compared with patients who received no prophy-
laxis.18 Other concerns that remain to be addressed include
the potential for the development of bacterial resistance,19 the
opportunity for fungal infections, and the issue of whether
prophylactic use of fluoroquinolones will later impact on the
choice of empiric therapy for infections. Defining the popu-
lation of patients most likely to benefit from prophylaxis
would be valuable to ensure appropriate use of antibiotics and
to preserve their utility for empiric therapy.
Older patients with advanced NSCLC are particularly
vulnerable to the effects of chemotherapy, which include
hematologic toxicity and associated infections. The subgroup
of patients aged 70 years in this study demonstrated a
median time to infection of 69 days with levofloxacin versus
27 days with placebo. In patients 70 years, the correspond-
ing values were 65 days for levofloxacin versus 69 days for
placebo. No clinically noteworthy differences in toxicity
were observed in the subgroup of patients 70 years of
age who received prophylaxis compared with the overall
population. Further studies of subgroups of patients with
different risk factors for infection will be useful to define
the patient populations that will benefit most from levo-
floxacin prophylaxis.
The rates of febrile neutropenia reported in this study
are comparable to rates reported in other studies of docetaxel/
carboplatin in older patients with advanced NSCLC.8 Rates
of infection for patients who received levofloxacin were
lower than those reported in the TAX 326 subgroup analysis.8
Grade 3/4 infections were reported in our study by 26.1% of
the placebo group versus 8.4% of the levofloxacin group. For
comparison, in the subgroup analysis of elderly patients (65
years) in the TAX 326 study who received docetaxel/carbo-
platin, the rate of grade 3/4 infections was 15.4%.8 There was
one death as a result of infection (grade 5) in each treatment
group in this study.
The emergence of resistance to levofloxacin was not
monitored in this study. However, the development of bac-
terial resistance was not expected to be an issue because
levofloxacin was only administered for 7 days. This may be
worth assessing in future studies to guide appropriate use
of fluoroquinolones for antibacterial prophylaxis in pa-
tients with cancer.
In clinical practice, older patients with advanced
NSCLC are less likely to receive chemotherapy and are often
undertreated. This may contribute to the lower survival rates
reported in this group of patients.20 Treatment strategies are
needed to minimize the adverse effects of chemotherapy in
these patients. Larger studies of the use of prophylactic
antibiotics are warranted and may show a survival benefit
because of reduction in infection-related mortality, which this
study was not designed to demonstrate.
In conclusion, this study has demonstrated that do-
cetaxel/carboplatin chemotherapy with levofloxacin prophy-
laxis is well tolerated in elderly patients with advanced
NSCLC and is associated with a lower rate of infection
compared with the chemotherapy regimen given without
levofloxacin prophylaxis. Nevertheless, additional prophylac-
tic use of granulocyte macrophage colony-stimulating factor
should be considered in some patients to avoid dose reduc-
tions of chemotherapy and cases of febrile neutropenia,
especially in those with comorbidities and limited organ
function.
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